In 2025, the total volume of online sales and reservations for pharmacy assortment products (medicines + parapharmaceuticals) reached RUB 578.6 billion (in final consumption prices, including VAT). The growth rate compared to 2024 in Russian currency stands at an impressive 33.8%. However, it should be noted that the pace of e-com development slowed steadily over the past year, with the fourth quarter being particularly "challenging" for this channel—if such a term can be applied to a +32% growth rate. At the same time, the growth rates of the online channel in Russian pharma retail significantly outpaced the overall revenue dynamics of Russian pharmacies, which stood at 12.1% in 2025. Furthermore, pharmacy sales in 2025 grew exclusively due to the medicinal product assortment, while demand for parapharmaceuticals showed negative dynamics (-1.4%), representing an absolute loss of RUB 6.3 billion.

The total share of the online channel, including reservations, accounted for 24.6% (in RUB) of the overall market volume by the end of 2025, a year-on-year increase of 4 percentage points. The role of online pharmacy sales with delivery to the consumer is significantly more modest. According to the database "Retail Audit of Drug Sales in Russia (Total Sell-Out)" from the analytical company RNC Pharma, 44.6 million packages of medicines were sold in this format in 2025, amounting to RUB 20.5 billion (in retail prices, including VAT). This represents just under 1.1% of the total Russian pharmaceutical retail market. Throughout the year, the growth rate here significantly outpaced the overall development of pharmaceutical e-com but nearly aligned with it by year-end—drug sales with delivery grew by 32.5% in ruble terms over the year.

Among the TOP-20 players in the e-com channel in 2025, there were no dramatic shifts, with the exception of the Polza.ru project by the distributor "Pulse." The company's online revenue more than doubled over the year, naturally impacting its position in the ranking: it now holds 9th place, compared to 12th a year earlier. Incidentally, the entity has maintained its growth rate for the second consecutive year, and given the scale of its parent company, it is practically destined to enter the top five. The second-best result in terms of growth dynamics was achieved by the "Yuteka" project (+84%), which ended the year in 4th place in the ranking by total turnover. Among the online projects of major pharmacy chains, "Rigla" demonstrated the most pronounced dynamics (+72%). The company has consistently pursued an expansive growth strategy and is currently one of the leaders in acquiring retail assets; their integration into the business is an obvious driver for the development of its e-com direction. The online channel of the "Planeta Zdorovya" chain also showed fairly high dynamics (+55%). However, this is not so much about global expansion—although the organization grew by 329 pharmacies over the year—but rather about the qualitative development of its online direction. The minimal dynamics in the top tier were exhibited by "Eapteka" and "ASNA," which grew by 1% and 3% respectively over the year.

Table. TOP-20 Pharmacy Chains and Associations by Share of Sales via Own Online Services in 2025

* Among the representatives of the e-com segment, we include only organizations whose core assortment includes medicinal products. These volumes also do not include revenue from participants in the gray online business related to supplies to Russia.